China Infrastructure Construction Corp.
CHNC
Other OTC0.00
USD
+0.00
- -
CIK
0001411057
Return %
Stock
S&P500
1Y
-64.29
18.99
3Y
150.00
64.75
5Y
-96.77
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Dante Picazo
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 6201 Bonhomme Road Houston TX United States of America 91789
- IPO Date
- Sep 8, 2009
- CIK
- 0001411057
- Website
- chnc-hdh.com
- Similar Companies
- Business
- China Infrastructure Construction Corp. (CHNC) provides educational systems focused on medical cannabis through in-person programs in cities across the United States and six countries in Latin America, as well as online education worldwide; it offers services in therapeutic areas including clinical trials and treatments for sleep disorders with associated infertility through its fertility and sleep center in Houston, Texas; and delivers education, consulting, digital publishing, marketing, and franchising related to medical cannabis via its Pharmacology University. The company, founded in 2003 and headquartered at 6201 Bonhomme Road in Houston, Texas, operates primarily in the medical and healthcare education sector, targeting healthcare professionals, patients, and institutions in North America and Latin America with approximately 389 employees. CHNC previously provided concierge medicine through its wholly owned subsidiary Hippocrates Direct Healthcare, LLC, but terminated this business during the quarter ended August 31, 2020; it acquired Precision Research Institute, LLC in March 2019 for its clinical trials capabilities, which merged into the company in August 2020; and completed a significant merger with Pharmacology University, Inc. on December 20, 2019, issuing over 4.8 billion common shares and 2 million Series A convertible preferred shares, resulting in a change of control with current president Dante Picazo as the principal shareholder.
CHNC Endeavors in Artificial Intelligence Systems for Its Educational Content
CHNC to Seek Up to $3 Million Funding for Expansion of Existing Product Lines and Development of New Cannabis-Derived Therapeutics
CHNC's Shareholders Rewarded with Astonishing Investment Return of Over 2500% During this Last Year
CHNC Expands Distribution of Its Educational Training Programs Through Leading Online Digital Distributors
CHNC Announces Name Change to Cannabis Bioscience International Holdings, Inc.
CHNC: Intensity, Determination and a Magical Unwavering Direction Transports CHNC to Become the Macondo of Medical Cannabis Research